Works by Kaku, Kohei

Results: 254

Ice Cube Tray-Shaped Insulin Lipoatrophy Throughout the Abdomen in a Subject With Type 2 Diabetes.

Published in:

2016

By:

Kenji Kohara;
Hideaki Kaneto;
Shinji Kamei;
Masashi Shimoda;
Sumiko Hamamoto;
Kazuhito Tawaramoto;
Michihiro Matsuki;
Tomoatsu Mune;
Kohei Kaku;
Kohara, Kenji;
Kaneto, Hideaki;
Kamei, Shinji;
Shimoda, Masashi;
Hamamoto, Sumiko;
Tawaramoto, Kazuhito;
Matsuki, Michihiro;
Mune, Tomoatsu;
Kaku, Kohei

Publication type:

Letter

Insulin administration to an abdominal insulin ball that triggered the onset of diabetic ketoacidosis accompanied by Hamman's syndrome in a patient with type 1 diabetes mellitus.

Published in:

Kawasaki Medical Journal, 2024, v. 50, p. 69, doi. 10.11482/KMJ-E202450069

By:

Masato KUBO;
Tomohiko KIMURA;
Kaio TAKAHASHI;
Yukino KATAKURA;
Fuminori TATSUMI;
Masashi SHIMODA;
Shuhei NAKANISHI;
Tomoatsu MUNE;
Kohei KAKU;
Hideaki KANETO

Publication type:

Article

A case of Sheehan syndrome with early postpartum panhypopituitarism and long-term partial improvement of endocrine function.

Published in:

Kawasaki Medical Journal, 2024, v. 50, p. 55, doi. 10.11482/KMJ-E202450055

By:

Yuichiro IWAMOTO;
Fuminori TATSUMI;
Mana OHNISHI;
Yukino KATAKURA;
Tomohiko KIMURA;
Masashi SHIMODA;
Shuhei NAKANISHI;
Kohei KAKU;
Tomoatsu MUNE;
Hideaki KANETO

Publication type:

Article

Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study.

Published in:

Journal of Diabetes Research, 2018, p. 1, doi. 10.1155/2018/9435401

By:

Hirukawa, Hidenori;
Kamei, Shinji;
Kimura, Tomohiko;
Obata, Atsushi;
Kohara, Kenji;
Tatsumi, Fuminori;
Shimoda, Masashi;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.

Published in:

Journal of Diabetes Research, 2018, p. 1, doi. 10.1155/2018/6470137

By:

Kamei, Shinji;
Iwamoto, Masahiro;
Kameyama, Miyuki;
Shimoda, Masashi;
Kinoshita, Tomoe;
Obata, Atsushi;
Kimura, Tomohiko;
Hirukawa, Hidenori;
Tatsumi, Fuminori;
Kohara, Kenji;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.

Published in:

Journal of Diabetes Research, 2017, p. 1, doi. 10.1155/2017/5856475

By:

Shimoda, Masashi;
Miyoshi-Takai, Maiko;
Irie, Shintaro;
Tanabe, Akihito;
Obata, Atsushi;
Okauchi, Seizo;
Hirukawa, Hidenori;
Kimura, Tomohiko;
Kohara, Kenji;
Kamei, Shinji;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Blocking mineralocorticoid signaling with esaxerenone reduces atherosclerosis in hyperglycemic ApoE KO mice without affecting blood pressure and glycolipid metabolism.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-95324-z

By:

Iwamoto, Hideyuki;
Sanada, Junpei;
Kimura, Tomohiko;
Shimoda, Masashi;
Iwamoto, Yuichiro;
Dan, Kazunori;
Fushimi, Yoshiro;
Katakura, Yukino;
Nogami, Yuka;
Shirakiya, Yoshiko;
Yamasaki, Yuki;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Chronic kidney disease risk assessment: Findings from backward‐looking study using annual health check‐up data in Japan.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 3686, doi. 10.1111/dom.16390

By:

Fukai, Chihaya;
Chiba, Shumpei;
Itoga, Takaaki;
Kobayashi, Gen;
Kaku, Kohei

Publication type:

Article

Efficacy and safety of imeglimin add‐on to DPP‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 6, p. 3212, doi. 10.1111/dom.16336

By:

Kaku, Kohei;
Shimoda, Masashi;
Osonoi, Takeshi;
Iwamoto, Masahiro;
Kaneto, Hideaki

Publication type:

Article

Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 12, p. 5982, doi. 10.1111/dom.15972

By:

Iwamoto, Yuichiro;
Kimura, Tomohiko;
Dan, Kazunori;
Iwamoto, Hideyuki;
Sanada, Junpei;
Fushimi, Yoshiro;
Katakura, Yukino;
Shimoda, Masashi;
Yamasaki, Yuki;
Nogami, Yuka;
Shirakiya, Yoshiko;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4366, doi. 10.1111/dom.15784

By:

Iwamoto, Hideyuki;
Kimura, Tomohiko;
Fushimi, Yoshiro;
Iwamoto, Masahiro;
Tatsumi, Fuminori;
Sanada, Junpei;
Iwamoto, Yuichiro;
Katakura, Yukino;
Shimoda, Masashi;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data‐driven cluster analysis: A post‐hoc analysis of imeglimin clinical trial data.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3732, doi. 10.1111/dom.15716

By:

Hagi, Katsuhiko;
Kochi, Kenji;
Watada, Hirotaka;
Kaku, Kohei;
Ueki, Kohjiro

Publication type:

Article

C‐peptide index at 2 h post‐meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2761, doi. 10.1111/dom.15595

By:

Iwamoto, Yuichiro;
Kimura, Tomohiko;
Shimoda, Masashi;
Morimoto, Yuichi;
Watanabe, Yuki;
Itoh, Takashi;
Sasaki, Taku;
Mori, Shigehito;
Kubo, Masato;
Takenouchi, Haruka;
Dan, Kazunori;
Iwamoto, Hideyuki;
Sanada, Junpei;
Fushimi, Yoshiro;
Katakura, Yukino;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2339, doi. 10.1111/dom.15548

By:

Iwamoto, Yuichiro;
Kimura, Tomohiko;
Dan, Kazunori;
Iwamoto, Hideyuki;
Sanada, Junpei;
Fushimi, Yoshiro;
Katakura, Yukino;
Shimoda, Masashi;
Nogami, Yuka;
Shirakiya, Yoshiko;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study)

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3632, doi. 10.1111/dom.15258

By:

Kimura, Tomohiko;
Katakura, Yukino;
Shimoda, Masashi;
Kawasaki, Fumiko;
Yamabe, Mizuho;
Tatsumi, Fuminori;
Matsuki, Michihiro;
Iwamoto, Yuichiro;
Anno, Takatoshi;
Fushimi, Yoshiro;
Kamei, Shinji;
Kimura, Yukiko;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2469, doi. 10.1111/dom.14836

By:

Matsubayashi, Yasuhiro;
Yoshida, Alkihiro;
Suganami, Hideki;
Oe, Momoko;
Sato, Takaaki;
Yaguchi, Yuta;
Fujihara, Kazuya;
Yamada, Takaho;
Tanaka, Shiro;
Kaku, Kohei;
Sone, Hirohito

Publication type:

Article

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 662, doi. 10.1111/dom.14626

By:

Kaku, Kohei;
Wanner, Christoph;
Anker, Stefan D.;
Pocock, Stuart;
Yasui, Atsutaka;
Mattheus, Michaela;
Lund, Søren S.

Publication type:

Article

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 609, doi. 10.1111/dom.14613

By:

Dubourg, Julie;
Fouqueray, Pascale;
Quinslot, Damien;
Grouin, Jean‐Marie;
Kaku, Kohei

Publication type:

Article

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 9, p. 2099, doi. 10.1111/dom.14448

By:

Kaku, Kohei;
Kadowaki, Takashi;
Seino, Yutaka;
Okamoto, Taro;
Shirakawa, Masayoshi;
Sato, Asako;
O'Neill, Edward A.;
Engel, Samuel S.;
Kaufman, Keith D.

Publication type:

Article

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1660, doi. 10.1111/dom.14387

By:

Matsubayashi, Yasuhiro;
Yoshida, Akihiro;
Suganami, Hideki;
Oe, Momoko;
Sato, Takaaki;
Yaguchi, Yuta;
Fujihara, Kazuya;
Yamada, Takaho;
Tanaka, Shiro;
Kaku, Kohei;
Sone, Hirohito

Publication type:

Article

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1342, doi. 10.1111/dom.14346

By:

Seino, Yutaka;
Kaku, Kohei;
Kadowaki, Takashi;
Okamoto, Taro;
Sato, Asako;
Shirakawa, Masayoshi;
O'Neill, Edward A.;
Engel, Samuel S.;
Kaufman, Keith D.

Publication type:

Article

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1242, doi. 10.1111/dom.14331

By:

Kadowaki, Takashi;
Seino, Yutaka;
Kaku, Kohei;
Okamoto, Taro;
Kameya, Miho;
Sato, Asako;
Hirano, Tomona;
Oshima, Nobuyuki;
Gantz, Ira;
O'Neill, Edward A.;
Engel, Samuel S.

Publication type:

Article

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 6, p. 947, doi. 10.1111/dom.13980

By:

Matsubayashi, Yasuhiro;
Yoshida, Akihiro;
Suganami, Hideki;
Osawa, Taeko;
Furukawa, Kazuo;
Suzuki, Hiroshi;
Fujihara, Kazuya;
Tanaka, Shiro;
Kaku, Kohei;
Sone, Hirohito

Publication type:

Article

Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 2, p. 222, doi. 10.1111/dom.13890

By:

Sato, Yuichi;
Nunoi, Kiyohide;
Kaku, Kohei;
Yoshida, Akihiro;
Suganami, Hideki

Publication type:

Article

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2674, doi. 10.1111/dom.13856

By:

Kaku, Kohei;
Araki, Eiichi;
Tanizawa, Yukio;
Ross Agner, Bue;
Nishida, Tomoyuki;
Ranthe, Mattis;
Inagaki, Nobuya

Publication type:

Article

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2674, doi. 10.1111/dom.13856

By:

Kaku, Kohei;
Araki, Eiichi;
Tanizawa, Yukio;
Ross Agner, Bue;
Nishida, Tomoyuki;
Ranthe, Mattis;
Inagaki, Nobuya

Publication type:

Article

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 10, p. 2284, doi. 10.1111/dom.13807

By:

Kaku, Kohei;
Isaka, Hiroyuki;
Sakatani, Taishi;
Toyoshima, Junko

Publication type:

Article

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1715, doi. 10.1111/dom.13731

By:

Nunoi, Kiyohide;
Sato, Yuichi;
Kaku, Kohei;
Yoshida, Akihiro;
Suganami, Hideki

Publication type:

Article

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1445, doi. 10.1111/dom.13679

By:

Kaku, Kohei;
Isaka, Hiroyuki;
Toyoshima, Junko;
Sakatani, Taishi

Publication type:

Article

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 1, p. 136, doi. 10.1111/dom.13496

By:

Kaku, Kohei;
Haneda, Masakazu;
Tanaka, Yuko;
Lee, Ganghyuck;
Shiki, Kosuke;
Miyamoto, Yuki;
Solimando, Fernando;
Lee, Jisoo;
Lee, Christopher;
George, Jyothis

Publication type:

Article

Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β‐cells in db/db mice: The earlier and longer, the better.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2442, doi. 10.1111/dom.13400

By:

Kimura, Tomohiko;
Obata, Atsushi;
Shimoda, Masashi;
Okauchi, Seizo;
Kanda‐kimura, Yukiko;
Nogami, Yuka;
Moriuchi, Saeko;
Hirukawa, Hidenori;
Kohara, Kenji;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2490, doi. 10.1111/dom.13397

By:

Kaku, Kohei;
Kuroda, Shingo;
Ishida, Kazuyuki;
Umeda, Yuusuke

Publication type:

Article

This is in reply to the Letter by Kahathuduwa et al. titled “Unaccounted for regression to the mean renders conclusion of article titled ‘Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin’ unsubstantiated”

Published in:

2018

By:

Ouchi, Motoshi;
Oba, Kenzo;
Suganami, Hideki;
Yoshida, Akihiro;
Fujita, Tomoe;
Suzuki, Tatsuya;
Yasutake, Masahiro;
Kaku, Kohei

Publication type:

Letter to the Editor

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1202, doi. 10.1111/dom.13218

By:

Kaku, Kohei;
Yamada, Yuichiro;
Watada, Hirotaka;
Abiko, Atsuko;
Nishida, Tomoyuki;
Zacho, Jeppe;
Kiyosue, Arihiro

Publication type:

Article

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1176, doi. 10.1111/dom.13213

By:

Terauchi, Yasuo;
Tamura, Masahiro;
Senda, Masayuki;
Gunji, Ryoji;
Kaku, Kohei

Publication type:

Article

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 1061, doi. 10.1111/dom.13170

By:

Ouchi, Motoshi;
Jutabha, Promsuk;
Morita, Asuka;
Hayashi, Keitaro;
Fujita, Tomoe;
Anzai, Naohiko;
Oba, Kenzo;
Kaku, Kohei;
Suganami, Hideki;
Yoshida, Akihiro;
Fukunaka, Yasunori;
Otani, Naoyuki;
Suzuki, Tatsuya;
Yasutake, Masahiro

Publication type:

Article

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 812, doi. 10.1111/dom.13152

By:

Inagaki, Nobuya;
Harashima, Shin‐ichi;
Kaku, Kohei;
Kondo, Kazuoki;
Maruyama, Nobuko;
Otsuka, Makiko;
Kawaguchi, Yutaka;
Iijima, Hiroaki

Publication type:

Article

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy ( J-STEP/ INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1397, doi. 10.1111/dom.12957

By:

Terauchi, Yasuo;
Tamura, Masahiro;
Senda, Masayuki;
Gunji, Ryoji;
Kaku, Kohei

Publication type:

Article

Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 463, doi. 10.1111/dom.12837

By:

Kaku, Kohei;
Sumino, Shuuji;
Katou, Masafumi;
Nishiyama, Yuya;
Kinugawa, Yoshinobu

Publication type:

Article

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.

Published in:

2019

By:

Kaku, Kohei;
Kisanuki, Koichi;
Shibata, Mari;
Oohira, Takashi

Publication type:

journal article

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.

Published in:

2017

By:

Tanaka, Hiroyuki;
Takano, Kazuhiko;
Iijima, Hiroaki;
Kubo, Hajime;
Maruyama, Nobuko;
Hashimoto, Toshio;
Arakawa, Kenji;
Togo, Masanori;
Inagaki, Nobuya;
Kaku, Kohei

Publication type:

journal article

Erratum to: Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus.

Published in:

2014

By:

Jung, Jin;
Kaku, Kohei;
Kim, Jae;
Kim, Jung-Ryul;
Ko, Jae-Wook;
Lee, Soo-Youn;
Huh, Wooseong

Publication type:

Correction Notice

Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus.

Published in:

Advances in Therapy, 2013, v. 30, n. 11, p. 1018, doi. 10.1007/s12325-013-0072-x

By:

Jung, Jin Ah;
Kaku, Kohei;
Kim, Jae Hyeon;
Kim, Jung-Ryul;
Ko, Jae-Wook;
Lee, Soo-Youn;
Huh, Wooseong

Publication type:

Article

HSD11B2 CA-repeat and sodium balance.

Published in:

Hypertension Research, 2013, v. 36, n. 7, p. 614, doi. 10.1038/hr.2013.13

By:

Mune, Tomoatsu;
Morita, Hiroyuki;
Takada, Nobuki;
Yamamoto, Yoritsuna;
Isomura, Yukinori;
Suwa, Tetsuya;
Takeda, Jun;
White, Perrin C;
Kaku, Kohei

Publication type:

Article

Molecular Mechanism of Pancreatic β-Cell Failure in Type 2 Diabetes Mellitus.

Published in:

Biomedicines, 2022, v. 10, n. 4, p. 818, doi. 10.3390/biomedicines10040818

By:

Kaneto, Hideaki;
Kimura, Tomohiko;
Shimoda, Masashi;
Obata, Atsushi;
Sanada, Junpei;
Fushimi, Yoshiro;
Matsuoka, Taka-aki;
Kaku, Kohei

Publication type:

Article

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-84488-9

By:

Iwamoto, Yuichiro;
Kimura, Tomohiko;
Dan, Kazunori;
Iwamoto, Hideyuki;
Sanada, Junpei;
Fushimi, Yoshiro;
Katakura, Yukino;
Shimoda, Masashi;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

The impact of grip strength, waist circumference, and body mass index on Hemoglobin A1c value: Cross-sectional study using outpatient clinical data in Japanese elderly patients with type 2 diabetes mellitus.

Published in:

Geriatrics & Gerontology International, 2024, v. 24, n. 4, p. 410, doi. 10.1111/ggi.14864

By:

Shuhei Nakanishi;
Masashi Shimoda;
Tomohiko Kimura;
Yukino Katakura;
Junpei Sanada;
Yoshiro Fushimi;
Yuichiro Iwamoto;
Hideyuki Iwamoto;
Tomoatsu Mune;
Kohei Kaku;
Hideaki Kaneto

Publication type:

Article

Replication study for the association of a single-nucleotide polymorphism, rs3746876, within KCNJ15, with susceptibility to type 2 diabetes in a Japanese population.

Published in:

Journal of Human Genetics, 2013, v. 58, n. 7, p. 490, doi. 10.1038/jhg.2013.28

By:

Fukuda, Hisashi;
Imamura, Minako;
Tanaka, Yasushi;
Iwata, Minoru;
Hirose, Hiroshi;
Kaku, Kohei;
Maegawa, Hiroshi;
Watada, Hirotaka;
Tobe, Kazuyuki;
Kashiwagi, Atsunori;
Kawamori, Ryuzo;
Maeda, Shiro

Publication type:

Article

Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus.

Published in:

Journal of Human Genetics, 2005, v. 50, n. 6, p. 283, doi. 10.1007/s10038-005-0253-9

By:

Maeda, Shiro;
Tsukada, Shuichi;
Kanazawa, Akio;
Sekine, Akihiro;
Tsunoda, Tatsuhiko;
Koya, Daisuke;
Maegawa, Hiroshi;
Kashiwagi, Atsunori;
Babazono, Tetsuya;
Matsuda, Masafumi;
Tanaka, Yasushi;
Fujioka, Tomoaki;
Hirose, Hiroshi;
Eguchi, Takashi;
Ohno, Yoichi;
Groves, Christopher;
Hattersley, Andrew;
Hitman, Graham;
Walker, Mark;
Kaku, Kohei

Publication type:

Article

Effects of Long-Term Treatment with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndrome.

Published in:

Leukemia & Lymphoma, 1995, v. 18, n. 5/6, p. 457, doi. 10.3109/10428199509059645

By:

Yoshida, Yataro;
Nakahata, Tatsutoshi;
Shibata, Akira;
Takahashi, Masuhiro;
Moriyama, Yoshiaki;
Kaku, Kohei;
Masaoka, Toru;
Kaneko, Toshio;
Miwa, Shiro

Publication type:

Article